Program
All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.
Thursday, October 19
Friday, October 20
Plenary Session 1: Novel Therapeutic Modalities
Plenary Session 2: Tumor Immunology and Microenvironment
Plenary Session 3: Tumor Metabolism
Proffered Talks I
Saturday, October 21
Plenary Session 4: Epigenetics and Epitranscriptomics
Keynote Lecture II
Special Lecture
Proffered Talks II
Plenary Session 5: 3D Genomes and Spatial Sequencing
sunday, October 22
Plenary Session 6: Emerging Molecular Targets
Plenary Session 7: Brain Metastasis
Thursday, October 19
Welcome and Opening Keynote
6:30-7:30 P.M.
Welcome from Conference Cochairs
Nada Jabado, McGill University, Montréal, Québec, Canada
Jeremy N. Rich, University of Pittsburgh, Pittsburgh, Pennsylvania
Michael D. Taylor, Texas Children’s Hospital, and Baylor College of Medicine, Houston, Texas
Opening Keynote
(Re)emerging principles of curative cancer therapy: will the rules apply to GBM?
William G. Kaelin Jr., Dana Farber Cancer Institute, Boston, Massachusetts
Opening Reception
7:30-9 P.M.
Friday, October 20
Continental Breakfast
7-8 A.M.
Plenary Session 1: Novel therapeutic modalities
Session Chair: Duane A. Mitchell, University of Florida Gainesville, Florida
8-10 A.M.
Cellular immunotherapy targeting malignant brain tumors
Duane A. Mitchell, University of Florida, Gainesville, Florida
GD2-CAR T Cells for Diffuse Midline Gliomas
Crystal Mackall, Stanford University, Stanford, California
CAR T cells for glioblastoma: Lessons learned and road ahead
Christine E. Brown, City of Hope, Duarte, California
Targeting Clonal Heterogeneity in Treatment-refractory Glioblastoma with Rationally Designed Immunotherapies
Sheila K. Singh, McMaster Children’s Hospital, Ontario, Canada
Break
10-10:30 A.M.
Plenary Session 2: Tumor Immunology and microenvironment
Session Chair: Peter Siegel, McGill University,Montréal, Québec, Canada
10:30 A.M.-12 P.M.
Brain tumors hijack neuronal mechanisms to thrive
Frank A. Winkler, German Cancer Research Center, Heidelberg, Germany
Decoding the language of tumor-neuron crosstalk in glioma
Benjamin Deneen, Baylor College of Medicine, Houston, Texas
Defining the immune landscapes of brain metastases
Peter Siegel, McGill University, Montréal, Québec, Canada
Patient Navigation Luncheon
12-1 P.M.
Brain Tumor Network Session: Commitment to Connection: How Patient Navigation Can Support the Neuro-Oncology Community
Session Chair: Jeremy N. Rich, University of Pittsburgh, Pittsburgh, Pennsylvania
12:30-1:30 p.m.
Panel Discussion
Clark Chen, University of Minnesota, Minneapolis, Minnesota
Courtney Burnett, HealthPartners, St. Paul, Minnesota
Jill Wyant, Madison Air, Minneapolis, Minnesota
BReak
1:30-2:00 p.m.
Plenary Session 3: tumor metabolism
Session Chair: Sameer Agnihotri, University of Pittsburgh, Pittsburgh, Pennsylvania
2-4:00 P.M.
Targeting metabolic complexity in glioblastoma stem cells
Jeremy N. Rich, University of Pittsburgh, Pittsburgh, Pennsylvania
Targeting hallmarks of brain tumors with metabolic vulnerabilities
Sameer Agnihotri, University of Pittsburgh, Pittsburgh, Pennsylvania
Oncometabolism in childhood brain cancer
Sriram Venneti, University of Michigan, Ann Arbor, Michigan
Break
4-4:15 P.M.
Proffered Talks I
Session Chair: Sriram Venneti, University of Michigan, Ann Arbor, Michigan
4:15-5:45 P.M.
Beta-adrenergic blockade licenses the use of immunotherapy in primary brain tumors and brain metastases
Selena Lorrey, Duke University, Durham, North Carolina
Uncovering novel therapeutic avenues for glioma by exploring the functional interplay of FGFR1, p53, and ribosome biogenesis
Mikael Lindström, Karolinska Institutet, Stockholm, Sweden
In vivo genome-wide CRISPR/Cas9 screens conducted in an immunocompetent mouse model of glioblastoma identify novel in vivo tumor liabilities and potential mechanisms of resistance to chimeric antigen receptor T-cell (CAR-T) therapy
Catherine Koch, MIT, Boston, Massachusetts
Targeting EPHB2/ABL1 restores anti-tumor immunity in a preclinical model of ependymoma
Taylor Uccello, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
CAR T-cell motility response to interstitial fluid flow and tumor microenvironment
Gabriela Geraldo Mendes, Virginia Tech University, Roanoke, Virginia
The role of tumor microenvironment in metastasis and relapses of medulloblastoma using immunocompetent mouse models
Niusha Khazaei, McGill University, Montreal, Québec, Canada
Lightning Talks I
Session Chair: Session Chair: Jeremy N. Rich, University of Pittsburgh, Pittsburgh, Pennslyvania
5:45-6 p.m.
Matthew Watowich, National Cancer Institute, Bethesda, Maryland
Charlotte Aitken, Tessa Jowell Brain Cancer Mission, London, United Kingdom
Emma Byrne, National Cancer Institute, Bethesda, Maryland
Poster Session A/Reception
6-8 P.M.
Saturday, October 21
Continental Breakfast
7-8 A.M.
Plenary Session 4: Epigenetics and Epitranscriptomics
Session Chair: Marco Gallo, Texas Children’s Hospital and Baylor College of Medicine, Houston, Texas
8-10 A.M.
Oncohistones: how to co-opt chromatin architecture to regulate developmental transcriptional programs
Nada Jabado, McGill University, Montréal, Québec, Canada
Elucidating the genetic alterations that predispose to the development and malignant progression of IDH-mutant glioma
Daniel Schramek, Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada
Rearrangements and the 3D genome
Rameen Beroukhim, Dana-Farber Cancer Institute, Boston, Massachusetts
KMT2D suppresses SHH-driven medulloblastoma progression and metastasis
Alexandra Joyner, Memorial Sloan Kettering Cancer Center, New York, New York
Break
10-10:30 A.M.
Keynote Lecture II
10:30-11:15 A.M.
Introduction of Keynote Speaker
Keynote Speaker
Metabolic reprogramming and cancer progression in patients
Ralph J. DeBerardinis, University of Texas Southwestern, Dallas, Texas
Special Lecture
11:15-11:45 A.M.
ZIC1: A Context Dependent Medulloblastoma Driver in the Rhombic Lip
Michael D. Taylor, Texas Children’s Hospital and Baylor College of Medicine, Houston, Texas
PROFFERED TALKS II
Session Chair: Michael E. Pacold, NYU Langone Health, New York, New York
11:45 A.M.-12:45 P.M.
Modeling epigenetic lesions that cause gliomas
Gilbert Rahme, Dana-Farber Cancer Institute, Boston, Massachusetts
H3.3K27M diffuse midline gliomas are sensitive to SWI/SNF chromatin remodeler degradation
Mateus Mota, University of Michigan, Ann Arbor, Michigan
Associations between PM 2.5, vegetation density and childhood brain tumors: a case-control registry-based study from Texas 1995-2011
Lindsay Williams, University of Minnesota, Minneapolis, Minnesota
Asc1lb progenitor-specific RB conditional inactivation in zebrafish models rare CNS primitive neuroectodermal tumors
Maura McGrail, Iowa State University, Ames, Iowa
Lunch (on own)
12:45-2:15 P.M.
PLENARY SESSION 5: 3D Genomes and Spatial Sequencing
Session Chair: Claudia Kleinman, McGill University, Montreal, Québec, Canada
2:15-3:45 P.M.
3D genomes in childhood brain cancers
Marco Gallo, Texas Children’s Hospital and Baylor College of Medicine, Houston, Texas
Epigenome engraving of cellular lineage in childhood high-grade gliomas
Claudia Kleinman, McGill University, Montreal, Québec, Canada
Deep learning-based virtual brain tumors for virtual clinical trials
Richard J. Gilbertson, University of Cambridge, Cambridge, England
Lightning Talks II
Session Chair: Nada Jabado, McGill University, Montréal, Québec, Canada
3:45-4:00 pm
Hannah Fuchs, Memorial Sloan Kettering Cancer Center, New York, New York
Stefania Faletti, Istituto Europeo di Oncologia, Milan, Italy
Xueqin Sherine Sun, Cold Spring Harbor Laboratory, New York, New York
poster session b/reception
4-6:00 P.M.
Sunday, October 22
Continental Breakfast
7-8 A.M.
Plenary Session 6: Emerging molecular targets
Session Chair: Joseph F. Costello, University of California, San Francisco, California
8-9:30 A.M.
Targeted therapies in childhood brain tumors; what can we learn from MAPK targeting in low grade glioma
Darren Hargrave, University College London Great Ormond Street Hospital, London, United Kingdom
Methylation-based diagnostics of CNS neoplasms
Kenneth D. Aldape, National Institute of Health, Bethesda, Maryland
Immortal and evolving: The formative years of tumor cells
Joseph F. Costello, University of California, San Francisco, San Francisco, California
break
9:30-9:45 A.m.
Plenary Session 7: brain metastasis
Session Chair: Priscilla K. Brastianos, Harvard Medical School/Massachusetts General Hospital, Boston, Massachusetts
9:45- 11:30 A.M.
Metabolic reprogramming in leptomeningeal metastasis
Adrienne A. Boire, Memorial Sloan Kettering Cancer Center, New York, New York
In search of precision medicine approaches for central nervous system metastases: from bench to bedside (and back to bench)
Priscilla K. Brastianos, Harvard Medical School/Massachusetts General Hospital, Boston, Massachusetts
Metabolic Dependencies of Brain Metastases
Michael E. Pacold, NYU Langone Health, New York, New York
Brain metastases roadmap reveals conserved regulatory dynamics rooted in dormant tumor cells
Remi Klotz, University of Maryland School of Medicine, Baltimore, Maryland